Quantcast
Last updated on April 16, 2014 at 14:04 EDT

Latest Interferon Stories

2012-11-15 08:29:59

Merck's hepatitis C treatment receives prestigious Innovative Product Award KIRKLAND, QC, Nov. 15, 2012 /CNW/ - Merck is proud to announce that VICTRELIS(TM) (boceprevir), a first-in-class oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic hepatitis C (CHC) genotype 1 infection, received the Prix Galien Canada 2012 - Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation,(1) this annual honour is...

2012-11-13 08:35:36

THOUSAND OAKS, Calif. and BRYAN, Texas, November 13, 2012 /PRNewswire-iReach/ -- ImmunGene, Inc. (ImmunGene) and Caliber Biotherapeutics, LLC (Caliber) announced today the launch of Valor Biotherapeutics, LLC (Valor), a joint venture focused on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers. The mAb-IFN fusion protein technology was invented in Professor Sherie Morrison's laboratory at the...

2012-11-10 12:21:24

BOSTON and RIDGEFIELD, Conn., Nov. 10, 2012 /PRNewswire/ -- Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV). A viral cure was achieved for 69 percent...

2012-11-10 08:21:55

BOSTON, Nov. 10, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced that the use of one once-daily pill of the investigational protease inhibitor simeprevir (TMC435) administered with pegylated interferon and ribavirin led to higher rates of sustained viral response at 24 weeks (SVR24) compared to placebo in patients with Metavir scores of F3 and F4 who were treatment naive and treatment experienced with genotype 1 hepatitis C. Simeprevir was also generally well...

2012-11-10 08:21:49

ABBOTT PARK, Ill., Nov. 10, 2012 /PRNewswire/ -- Results from Abbott's phase 2b clinical trial, "Aviator," demonstrated high sustained viral response rates at 12 weeks post-treatment (SVR(12)) in all 8- and 12-week arms, with combinations of direct acting antivirals (DAAs) given with and without ribavirin (RBV). Results will be presented at the President's Press Conference and the latebreaking clinical trials session at the Liver Meeting, the Annual Meeting of the American Association for the...

2012-11-02 11:25:50

BOSTON, Nov. 2, 2012 /PRNewswire/ -- Late-breaking Oral SessionMonday, November 12, 2012 - 3:00-4:30 pmAuditorium, Hynes Convention Center The six abstracts that will be presented at our late-breaking oral session relate to new therapies for patients with chronic liver diseases. Four of the six studies (see numbers 1 - 4 below) report on the results of oral therapy for the treatment of hepatitis C, a disease that affects more than 3 million Americans and that is currently...

New Treatment For Multiple Sclerosis Offers Promising Results
2012-11-01 09:25:28

Lawrence LeBlond for redOrbit.com - Your Universe Online A new drug to fight multiple sclerosis (MS) is showing promise as one of the “most effective” treatment options ever produced for the debilitating disease, according to UK researchers. The drug, which is used to ℠reboot´ a person´s immune system, has been shown to be effective in MS patients who have already failed to respond to the first drug with which they were treated, as well as those who have gone...

2012-11-01 07:31:14

STOCKHOLM, November 1, 2012 /PRNewswire/ -- - Companies to evaluate a two-drug combination of Medivir/Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue VX-135 - Phase II proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen Medivir AB (OMX: MVIR), announced today plans for a phase II...

2012-11-01 07:31:04

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step,...

2012-10-17 11:24:01

WATERTOWN, Mass., Oct. 17, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that Abbott initiated an interferon-free combination Phase 3 clinical trial for hepatitis C (HCV) that included the collaboration's protease inhibitor, ABT-450. This trial was initiated following the release of positive results from the study known as "Aviator", a...


Latest Interferon Reference Libraries

0_9255b919f71eff1fd4202c1dbb1795d2
2011-01-12 15:49:29

Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...

More Articles (1 articles) »